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Global return on investment and cost-effectiveness of 
WHO’s HEAR interventions for hearing loss: a modelling 
study
David Tordrup, Robert Smith, Kaloyan Kamenov, Melanie Y Bertram, Nathan Green, Shelly Chadha, WHO HEAR group*
Summary
Background To address the growing prevalence of hearing loss, WHO has identified a compendium of key evidence-
based ear and hearing care interventions to be included within countries’ universal health coverage packages. To 
assess the cost-effectiveness of these interventions and their budgetary effect for countries, we aimed to analyse the 
investment required to scale up services from baseline to recommended levels, and the return to society for every 
US$1 invested in the compendium.
Methods We did a modelling study using the proposed set of WHO interventions (summarised under the acronym 
HEAR: hearing screening and intervention for newborn babies and infants, pre-school and school-age children, 
older adults, and adults at higher risk of hearing loss; ear disease prevention and management; access to 
technologies such as hearing aids, cochlear implants, or hearing assistive technologies; and rehabilitation service 
provision), which span the life course and include screening and management of hearing loss and related ear 
diseases, costs and benefits for the national population cohorts of 172 countries. The return on investment was 
analysed for the period between 2020 and 2030 using three scenarios: a business-as-usual scenario, a progress 
scenario with a scale-up to 50% of recommended coverage, and an ambitious scenario with scale-up to 90% of 
recommended coverage. Using data for hearing loss burden from the Global Burden of Disease Study 2019, a 
transition model with three states (general population, diagnosed, and those who have died) was developed to 
model the national populations in countries. For the return-on-investment analysis, the monetary value of disability-
adjusted life-years (DALYs) averted in addition to productivity gains were compared against the investment required 
in each scenario.
Findings Scaling up ear and hearing care interventions to 90% requires an overall global investment of US$238∙8 billion 
over 10 years. Over a 10-year period, this investment promises substantial health gains with more than 130 million 
DALYs averted. These gains translate to a monetary value of more than US$1∙3 trillion. In addition, investment in 
hearing care will result in productivity benefits of more than US$2 trillion at the global level by 2030. Together, these 
benefits correspond to a return of nearly US$15 for every US$1 invested.
Interpretation This is the first-ever global investment case for integrating ear and hearing care interventions in 
countries’ universal health coverage services. The findings show the economic benefits of investing in this 
compendium and provide the basis for facilitating the increase of country’s health budget for strengthening ear and 
hearing care services.
Funding None.
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properly cited. This article shall not be used or reproduced in association with the promotion of commercial 
products, services or any entity. There should be no suggestion that WHO endorses any specific organisation, 
products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the 
article’s original URL.
Introduction
Hearing loss is a global public health challenge. Latest 
estimates reveal that hearing loss currently affects 
1∙59 billion people worldwide—ie, 20∙3% of the global 
population—of whom 430 million (5∙5%) have moderate 
or higher severity of hearing loss.1 By 2050, the number 
of people with hearing loss is anticipated to reach 
nearly 2∙5 billion, of whom 700 million will require 
interventions.2 When unaddressed, hearing loss has a 
huge negative effect at individual and societal levels. 
Hearing loss is the third leading cause for years lived with 
disability worldwide,3 affecting one’s quality of life, 
communication, cognition, education, employment, and 
social participation.4–9 At a societal level, unaddressed 
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hearing loss poses a huge economic burden, previously 
estimated as more than US$750 billion per year globally.10
Most people who have hearing loss can successfully 
benefit from existing and effective interventions. WHO 
has identified a compendium of key evidence-based 
interventions required for prevention, screening, 
diagnosis, and treatment, including rehabilitation of 
hearing loss and related ear diseases, which can be 
directly delivered through the health system and are 
essential to ensure that people have access to ear and 
hearing care.1 These interventions cover the whole life 
course and are summarised under the acronym HEAR, 
which refers to hearing screening and intervention for 
newborn babies and infants, preschool and school-age 
children, older adults, and adults at higher risk of 
hearing loss; ear disease prevention and management; 
access to technologies such as hearing aids, cochlear 
implants, or hearing assistive technologies; and 
rehabilitation service provision. The effective delivery 
of these interventions can only be possible through 
their inclusion within countries’ universal health 
coverage packages.
To integrate the HEAR interventions into their 
health systems, countries need to first assess the health 
benefits of such a package for universal health coverage. 
This assessment will include consideration of the 
cost-effectiveness of interventions (representing the 
interventions’ value for money), and their budgetary 
effect. An economic case for HEAR can be used to show 
the economic benefits of investing in this particular 
package as part of universal health coverage. It can also 
facilitate the increase of a country’s health budget for 
strengthening ear and hearing care services, and for a 
more efficient use of government resources.
We therefore aimed to provide the first-ever global 
investment case for integrating ear and hearing care 
interventions in countries as part of their universal health 
coverage package. More specifically, we aimed to explore 
the financial investment required between 2020 and 2030 
to scale up services from baseline to recommended levels, 
and the return to society for every US$1 invested in 
HEAR, including the health effect in disability-adjusted 




We did a modelling study in collaboration with the teams 
at WHO working on the World Report on Hearing,11 
which recommends the implementation of the HEAR 
interventions by its member states. Inputs were sought 
from and oversight provided by a group of technical 
experts representing different WHO regions and income 
levels. Using the proposed set of interventions, which 
span the life course and include screening and 
management of hearing loss and related ear diseases, 
costs and benefits for the national population cohorts of 
172 countries were modelled. These countries and those 
for which data gaps resulted in exclusion are listed in the 
appendix (pp 46–56). Country income groups were based 
on the World Bank country classification.12
Perspective, time horizon, and scenarios
Costs and benefits were determined from the health-care 
perspective and societal perspective separately. The health-
care perspective included direct costs to the health system 
of screening and treatment commodities and human 
resources. The societal perspective additionally included 
Research in context
Evidence before this study
The only global economic study on hearing loss to our knowledge 
was undertaken by WHO in 2017 to estimate the societal 
economic burden of unaddressed hearing loss, which equalled 
US$750 billion annually. This analysis differed substantially from 
the present work in terms of scope and the methodology (eg, 
productivity costs were considered only in countries with full 
employment, unlike in this study). The current study provides the 
first-ever global investment case for a recommended set of ear 
and hearing care interventions that countries can integrate in 
their universal health coverage service package.
Added value of this study
Our study analysed three different scenarios for upscaling the 
HEAR compendium of evidence-based interventions: business-
as-usual scenario, progress scenario, and ambitious scenario. 
The ambitious scenario estimates that US$239 billion would be 
needed to improve the coverage of HEAR to 90% over the next 
10 years. Even though this number might seem staggering, the 
ambitious scenario requires less than US$45 per person over 
10 years in high-income countries and less than US$20 per 
person in low-income countries. Over a 10-year period, such 
investment is expected to provide a return of nearly US$15 for 
every US$1 invested and result in health gains that translate to 
monetary values of more than US$1·3 trillion and productivity 
gains of more than US$2 trillion.
Implications of all the available evidence
The HEAR interventions are the first comprehensive 
compendium of evidence-based interventions promoted by 
WHO at the global level. This package includes interventions for 
prevention, identification, management, and rehabilitation of 
hearing loss and related ear diseases that span the life course 
and can be directly delivered through the health system in every 
country. On the basis of health and societal gains, the HEAR 
package represents an attractive opportunity for policy makers 
to invest in ear and hearing care.
See Online for appendix
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productivity benefits. The timeframe for estimating the 
return on investment was the 11-year period between 2020 
and 2030, corresponding to the Sustainable Development 
Goals period. The analysis was run for three scenarios: a 
business-as-usual scenario, representing a continuation of 
current levels of activity; a progress scenario, in which 
scale-up reaches 50% of recommended coverage (or 
remains at baseline coverage if already above 50%); and an 
ambitious scenario, in which scale-up reaches 90% of the 
recommended coverage. In most health interventions, a 
90% coverage achievement is what can be expected 
through sustained investment and strict policy 
implementation. Many countries have achieved 90% 
coverage for newborn hearing screening,13 but not for 
hearing screening and intervention in later life. Hence, 
achieving 90% coverage is an ambitious goal. The goal of 
50% coverage was arrived at through consensus during 
discussions with experts. This goal was based on trends 
observed in countries such as the UK where planning for 
newborn hearing screening started in 1997 and took more 
than 15  years (between 2001 and 2017) to achieve a 
coverage of more than 90%. Hence, a target of 50% was 
considered to be achievable with the political commitment 
and sustained investment that this Article and the World 
Report on hearing calls for. This target is also consistent 
with WHO’s approach in other fields, such as the resource 
requirements and cost-effectiveness estimates for scaling 
up hepatitis management.
Model structure
A transition model with three states (general population, 
diagnosed, and those who have passed away) was 
developed to model the national populations. Individuals 
transitioned from the general population to the diagnosed 
population on account of screening activity. Total 
populations by 1-year age groups and by severity of 
hearing loss were represented in the model (figure 1). For 
any country and any year in the model time horizon, the 
model quantified the number of individuals at different 
levels of hearing loss, for each age, as well as the number 
of individuals already screened for or diagnosed with 
hearing loss. Transition probabilities are a function of 
national screening rate, national burden of hearing loss, 
and national background mortality statistics, and are 
therefore not annotated on figure 1.
Transitions between states of the model were governed 
by the rate of screening, which is a function of the 
baseline screening rate and scale-up; the remaining 
number of unidentified individuals with hearing loss at 
each age and severity level relative to the size of the 
screened group; and the background mortality at each 
age, which defined transitions from all compartments to 
the dead compartment. National populations by age were 
sourced directly from the World Population Prospects, 
and mortality data by 5-year age groups from the same 
source were rescaled to estimate 1-year mortality rates.14 
Central parameters, their ranges, and data sources for the 
model are outlined in table 1. Central equations are 
provided in the appendix (pp 60–61). The model was 
coded in R (version 3.6.1).
Interventions and coverage
As the analysis considers HEAR in the context of universal 
health coverage, the model considers all population 
segments who might benefit from the HEAR 
interventions. To determine resource use and outcomes, 
individuals in the model were screened and managed 
according to age-specific protocols. WHO screening 
protocols corresponding to 100% coverage are outlined in 
the appendix (p 1), and coverage of these screening 
services were scaled according to the current coverage 
level. The full protocol consists of screening of all 
newborns, biannual screening of school age children 
(5–14 years), annual screening of occupational risk groups 
in the 15–49-year age group, biannual screening of adults 
aged 50–69 years, and annual screening of adults aged 70 
years or more. Screened individuals were either diagnosed 
with hearing loss or returned to the population eligible for 
screening. Additionally, children not covered by screening 
are managed on a presenting case basis, which could miss 
out those who develop hearing loss in this age group, but 
who fail to come into contact with the formal health 
system. This scenario implies that a small proportion of 
those in need of care might not be captured by this model. 
Individuals identified with hearing loss incurred 
management costs in the year they were diagnosed, and 
were not considered for further interventions over the 
time horizon of the model.
The level of baseline coverage of both screening services 
and interventions, expressed as a proportion of the WHO 
recommended screening or treatment protocol, was 
based on expert opinion aligned with WHO coverage 
assumptions for other non-communicable disease 
interventions:15,16 5% for low-income countries, 10% for 
lower-middle-income countries, and 15% for upper-
middle-income countries across all interventions. 
Baseline coverage for high-income countries was based 
on available evidence and expert opinion, and was 
estimated as 90% for newborn screening,13 50% for 
screening in children aged 5–14 years, 60% for screening 
in the 15–49-year risk groups, and 20% for remaining 
interventions (appendix p 57). Correspondingly, the 
proportion of hearing loss already identified and managed 
at baseline was assumed to be the same as the baseline 
screening and treatment coverage, and these individuals 
were not considered for further screening or interventions.
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We did not model specific risk factors for hearing loss 
within populations, except for the screening of high-
risk occupational groups. The occurrence of hearing 
loss is therefore assumed to be a uniformly distributed 
random process across the general population, and the 
efficiency of screening is therefore determined by the 
ratio of prevalent but unidentified cases of hearing 
loss to the total screened population. Once an individual 
is diagnosed with hearing loss, they are no longer 
screened.
Details about the interventions modelled across the life 
course along with the commodities and staff time 
required for these interventions are outlined in the 
appendix (pp 7–25). Briefly, the compendium of 
interventions includes the following groups: hearing 
screening in newborns and infants, pre-school and 
Values Low estimate High estimate Source
Baseline screening and service coverage (all 
age groups) 
Expert opinion15,16
Low-income countries 5% NA NA
Lower-middle-income countries 10% NA NA
Upper-middle-income countries 15% NA NA
Baseline screening and service coverage in 
high-income countries
Expert opinion*
Newborns 90% NA NA
0–1 years 20% NA NA
1–4 years 20% NA NA
5–14 years 50% NA NA
15–49 years 60% NA NA
50–69 years 20% NA NA
≥70 years 20% NA NA
National age-structured populations Country specific NA NA World Population Prospects14
National background mortality by age Country specific NA NA World Population Prospects14
Prevalence of hearing loss by country GBD 201917
Mild 8·2–24·7% NA NA
Moderate 1·3–7·8% NA NA
Moderately severe 0·4–2·1% NA NA
Severe 0·05–0·3% NA NA
Profound 0·09–0·3% NA NA
Complete 0·06–0·3% NA NA
Disutilities of hearing loss levels GBD 201917
Mild –0·01 50% of base case 150% of base case
Moderate –0·027 50% of base case 150% of base case
Moderately severe –0·092 50% of base case 150% of base case
Severe –0·158 50% of base case 150% of base case
Profound –0·204 50% of base case 150% of base case
Complete –0·215 50% of base case 150% of base case
Relative reduction in employment rate† for 
moderately severe to complete hearing loss
25·2%‡ NA NA UK Department for Work and 
Pensions18
Adult employment-to-population ratio by 
age and sex
Country specific NA NA ILO19
Unemployment rate by sex and age Country specific NA NA ILO20
Gross domestic product per capita in 
purchasing power parity
Country specific NA NA World Bank21
Duration of treatment benefits 7 years or remaining life expectancy 4 years 10 years Assumption
Treatment effectiveness
Hearing aid Disability level reduced by one level NA NA Expert opinion, aligned with 
GBD 2019 methodology22
Cochlear implants Complete or profound hearing loss 
transitions to moderate hearing loss
NA NA Expert opinion
Medical management Mild hearing loss transitions to no 
hearing loss
NA NA Expert opinion
(Table 1 continues on next page)
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school-age children, adults at higher risk of hearing 
loss, and older adults; ear disease identification and 
management; access to technologies with the objective to 
improve access to hearing aids, cochlear implants, and 
related services; and rehabilitation services.
Disease burden
The burden of hearing loss by country was estimated from 
the Global Burden of Disease Study 2019 (GBD 2019),3 
using the relative prevalence in the GBD 2019 and country 
populations from the World Population Prospects to 
estimate the total number of individuals in each category 
of hearing loss from 2020 to 2030. Categories of hearing 
loss were mild, moderate, moderately severe, severe, 
profound, and complete. To account for different burdens 
and interventions in different age groups, population and 
burden was modelled in 1-year age groups. Data for 
disease burden therefore comprised, for each country, the 
prevalence rate stratified by gender, 5-year age groups 
(from 0 years to >95 years), and severity level from the 
GBD 2019.
DALYs and treatment effect
DALYs averted were calculated based on disutilities 
associated with mild (–0∙01), moderate (–0∙027), 
moderately severe (–0∙092), severe (–0∙158), profound 
(–0∙204), and complete (–0∙215) hearing loss.2 Management 
of hearing loss results in improvement in disability as 
detailed in the appendix (pp 2–3). Briefly, individuals 
receiving hearing aids moved to one lower level of hearing 
loss disability, those receiving cochlear implants moved 
from complete or profound to moderate hearing loss 
disability, and mild hearing loss either remained as mild 
hearing loss disability if not actively treated, or moved to no 
disability if treated. Thus, for example, disutility for an 
individual with moderate hearing loss (–0∙027) who 
receives a hearing aid would improve to one lower level of 
hearing loss disability, being mild hearing loss (–0∙01). 
This effect would avert 0∙017 DALYs per year the individual 
survives, up to a maximum of 7 years.
We assumed a proportion of mild hearing loss 
would be due to otitis media or impacted wax; and, of 
these, a subset of individuals with otitis media would 
Values Low estimate High estimate Source
(Continued from previous page)
Unit costs, 2018 US$
Otoacoustic emissions 0·55 0·55 0·69 Expert opinion*
Auditory brainstem response 1·35 1·35 1·43 Expert opinion*
Hearing aid
Low power 50 50 306 Expert opinion*
High power 100 100 306 Expert opinion*
Medical management§ 0·5 0·25 1 Expert opinion*
Screening otoscope 0 0 0 Expert opinion*
Otoscope 0·01 0·01 0·02 Expert opinion*
Cochlear implant 6011·47 6011·43 6056·75 Expert opinion*
Audiometer 0·05 0·05 0·18 Expert opinion*
Grommet or tympanoplasty 40·18 40·18 90·5 Expert opinion*
Mastoidectomy 11·47 11·43 56·75 Expert opinion*
Tympanometer 0·19 0·19 0·27 Expert opinion*
App screening 0 0 0 Expert opinion*
Screening audiometer 0·03 0·03 0·08 Expert opinion*
Nurse Level 1 50% of base case 150% of base case WHO CHOICE23
Audiologist Level 4 50% of base case 150% of base case WHO CHOICE23
Ear, nose, and throat physician Level 4 50% of base case 150% of base case WHO CHOICE23
Rehabilitation Level 1 50% of base case 150% of base case WHO CHOICE23
General practitioner Level 2 50% of base case 150% of base case WHO CHOICE23
Technician Level 1 50% of base case 150% of base case WHO CHOICE23
Radiologist Level 3 50% of base case 150% of base case WHO CHOICE23
Radiology technician Level 1 50% of base case 150% of base case WHO CHOICE23
Anaesthetist Level 3 50% of base case 150% of base case WHO CHOICE23
Costs of staff types are country-specific and are detailed in the appendix (pp 27–33). Low values of staff costs for the sensitivity analysis are chosen as 50% of the WHO 
CHOICE value and high values as 150%. GBD 2019=Global Burden of Disease Study 2019. ILO=International Labour Organization. HEAR=hearing screening and intervention; 
ear disease prevention and management; access to technologies; and rehabilitation service provision. NA=not applicable. *WHO HEAR group, based on country-level 
expertise and programmatic work. †Percentage of people who are employed. ‡Relative reduction is calculated from employment rate in individuals with difficulty in hearing 
of 61·1% and employment rate in population without disability of 81·7%;18 employment rate in population without disability is 81·7%.18 §Antibiotics for otitis media. 
Table 1: Central parameters, unit costs, and low and high estimates for commodities used in HEAR interventions
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spontaneously recover without treatment. To avoid 
overestimating a benefit, for the proportion of hearing 
loss which was treated with medical (non-surgical) 
management, we therefore estimated 83∙5% of cases in 
children (0–14 years) and 98% of cases in adults 
(≥15  years) would have a DALY benefit from treatment 
(appendix pp 2–3). These estimates are based on available 
evidence24–26 and expert opinion. All treatments were 
assumed to yield a benefit for a maximum of 7 years in 
the base case, except for the 16∙5% of mild cases in 
children and 2% of mild cases in adults, who would 
recover spontaneously, and individuals who would die 
before 7 years. 7 years is the approximate useful life of the 
device in the case of hearing aids and cochlear implants, 
and considered to be a conservative estimate both for 
medical management, which averts chronic sequelae of 
infection, and surgery not requiring implants (eg, 
mastoidectomy or tympanoplasty).
Treatments for hearing loss confer no survival benefit, so 
DALYs averted are calculated on the basis of quality of life 
(disutility) alone. Discounted DALYs averted are calculated 
for each individual undergoing treatment. DALYs averted 
are calculated based on the effect of treatment on severity 
(change in disability level), and duration for which 
the treatment is effective (7 years). For all treatments 
initiated, DALY benefits were counted in full regardless of 
what year treatment was initiated—ie, benefit was not 
truncated if treatment was initiated near the end of the 
model time horizon. However, the duration of treatment 
effect also took into account mortality, using a life-table 
approach to avoid over-estimating DALYs for individuals 
who would die before 7 years. No further DALY benefit 
is accounted for in individuals who die in the 7 years 
following a hearing loss intervention. A full illustration of 
DALY calculations is given in the appendix (p 62).
Direct costs
All costs and benefits are discounted at 3% in the base 
case in line with the WHO CHOICE approach.27 All costs 
are presented in 2018 US$. Gross domestic product 
(GDP) per capita in purchasing power parity was inflated 
from the most recently available year to 2018 using the 
World Bank GDP deflator. The year of most recent GDP 
data along with details about labour market data is given 
in the appendix (pp 34–45).
The global unit costs (2018 US$) for interventions 
included in the analysis are calculated using a bottom-up 
or ingredients-based approach in line with previous 
WHO analyses.16 Unit costs are outlined in table 1, based 
on detailed commodity costs; useful life of devices and 
utilisation are further outlined in the appendix (pp 4–6). 
Staff costs are not included in global unit costs, as 
individual costs are available for each of the 172 countries 
modelled. Staff salaries per minute by level were 
extracted for each country from the WHO CHOICE 
database to estimate staff costs for each intervention 
(appendix pp 27–33). Low and high estimates for use in 
the sensitivity analysis are included.
Figure 2: Cumulative per capita discounted costs of screening and treatment by income level in the business-as-usual scenario, progress scenario, and 
ambitious scenario
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Total cost per intervention is calculated for each 
intervention using the proportion of the target group 
receiving the intervention (coverage), unit cost of 
equipment, and the type, number, and duration of 
consultations by staff type. Full details are enumerated in 
the appendix (pp 7–25). 
Return on investment was defined as the ratio of the 
discounted net benefit to costs (total monetised benefits 
minus total costs, divided by total costs).
Sensitivity analysis 
A series of univariate sensitivity analyses were done 
(rationale and results are shown in the appendix p 58). 
The analyses examined the relative return-on-investment 
effect of changes to the level of unemployment above 
which productivity benefits were quantified (6% cutoff), 
the WHO CHOICE salary data (50–150% variation), the 
time horizon for benefits (4–10 years), discount rate 
(0–5%), disutilities used for DALY calculations (50–150% 
variation), and costs of commodities (ranges shown in 
table 1).
Model validation
The model was validated in a three-step process. First, 
unit tests of the code were done to check the results of 
central script functions. Second, the logic of the code was 
independently reviewed by one author (NG) during the 
coding process. Third, two authors (NG and DT) 
independently calculated the total avoidable burden of 
hearing loss and costs for a sample of countries and 
compared the results with the model output (appendix 
pp 63–73).
Results
The cumulative discounted cost of screening and treatment 
in the three scenarios, expressed as US$ per capita by 
income group, is shown in figure 2. Overall, the total 
cumulative cost of the package of hearing loss increases by 
scenario and by country income group. At current levels of 
screening and intervention coverage (ie, business as 
usual), total costs over the model time horizon range from 
US$4∙44 per capita in low-income countries to US$29∙47 
per capita in high-income countries. In the progress 
scenario, total costs over the time horizon reach US$14∙30 
per capita in low-income countries and US$37∙62 per 
capita in high-income countries. In the ambitious scenario, 
representing 90% coverage of hearing loss services, total 
costs over the model time horizon are US$19∙39 per capita 
in low-income countries and US$43∙10 per capita in 
high-income countries. The gradient in costs between 
income levels is driven by higher consultation costs in 
higher-income countries than in lower-income countries 
(appendix pp 27–33).
Figure 3 shows the cumulative discounted DALY gains 
in the three scenarios. At current levels of screening and 
intervention coverage, DALYs increase over time because 
of individuals with hearing loss continuously being 
identified and treated in countries at all income levels. 
Figure 3: Cumulative DALYs averted per 100 000 population by income level in the business-as-usual scenario, progress scenario, and ambitious scenario
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Higher DALY gains in higher-income countries than in 
lower-income countries are due to greater levels of 
service coverage at baseline (appendix p  57). However, 
DALY gains increase more rapidly in the progress and 
ambitious scenarios, as a greater proportion of prevalent 
cases of hearing loss are identified and managed. Over 
the time horizon of the model, at current levels of 
screening and intervention, total DALYs averted per 
100 000 population range from 206 in low-income 
countries to 1508 in high-income countries. In the 
progress scenario, the range is from 679 in low-income 
countries to 1914 in high-income countries. In the 
ambitious scenario, scale-up to 90% service coverage 
results in 898 DALYs averted per 100 000 population in 
low-income countries, ranging up to 2170 DALYs averted 
per 100 000 population in high-income countries.
Total cost and total DALYs averted for the progress and 
ambitious scenarios are shown for comparison in 
table  2. The effect of the ambitious scenario is 
approximately twice the amount of DALYs averted in the 
business-as-usual scenario, although costs of the HEAR 
interventions are also greater by a similar magnitude. 
Productivity benefits are almost US$1 trillion higher in 
the ambitious scenario than in the business-as-usual 
scenario.
The return-on-investment results for the ambitious 
scenario are grouped by the World Bank income groups 
and are shown in table 3. The total costs of the 
interventions increase with income level, explained by 
higher salaries of health-care workers. Similarly, the 
productivity and monetised health benefits increase by 
income level, explained by increasing GDP per capita. 
The return on investment ranges from –0∙07 in low-
income countries, signifying an estimated cost of 
implementation that is marginally higher than total 
benefits, to 36∙59 in high-income countries. At a global 
level, the return on investment of screening and 
managing hearing loss as outlined in the ambitious 
scenario is 14∙81. From a health system perspective, the 
average incremental cost-effectiveness ratio (ACER) 
ranges from US$1633 per DALY averted in upper-middle 
income countries, to US$2161 per DALY averted in low-
income countries in the ambitious scenario. From a 
societal perspective, which includes productivity benefits, 
the interventions are dominant in all income groups, 
except for low-income countries where the societal ACER 
is US$1159 per DALY averted in the ambitious scenario.
Comparing the costs and outcomes of the ambitious 
scenario with the business-as-usual scenario, the 
incremental cost-effectiveness ratios of screening and 
management of hearing loss are shown in table 4. The 
additional DALYs gained in the ambitious scenario 
ranged from over 6 million in low-income countries to 
more than 28 million in lower-middle income countries. 
Gains in productivity benefit ranged from more than 
US$6 billion in low-income countries to more than 
US$419 billion in high-income countries.















Low-income countries 6 116 611 $12 898 $6345 $6119 $2109 $1071 –0·03
Lower-middle-income countries 37 319 524 $65 705 $182 868 $147 043 $1761 –$3139 4·02
Upper-middle-income countries 42 746 278 $69 275 $720 277 $404 064 $1621 –$15 229 15·23
High-income countries 23 939 788 $47 064 $1 194 544 $595 006 $1966 –$47 932 37·02
Total 110 122 200 $194 942 $2 104 034 $1 152 233 $1770 –$17 336 15·70
Ambitious scenario
Low-income countries 8 090 085 $17 486 $8108 $8078 $2161 $1159 –0·07
Lower-middle-income countries 46 790 337 $84 142 $222 393 $183 835 $1798 –$2955 3·83
Upper-middle-income countries 50 949 302 $83 219 $843 739 $481 285 $1633 –$14 927 14·92
High-income countries 27 152 154 $53 912 $1 351 757 $674 715 $1986 –$47 799 36·59
Total 132 981 877 $238 759 $2 425 997 $1 347 913 $1795 –$16 448 14·81
Costs are given in 2018 US$. ACER=average incremental cost-effectiveness ratio. DALYs=disability-adjusted life-years. HEAR=hearing screening and intervention; ear disease 
prevention and management; access to technologies; and rehabilitation service provision. *Total costs divided by total DALYs averted. †Total costs minus total productivity 
benefits, divided by total DALYs averted. In cases where there was a positive DALY gain, and productivity benefits are greater than total costs, the intervention is dominant 
from a societal perspective. ‡Return on investment was calculated as total monetised benefits (productivity plus monetised DALYs) minus total costs, divided by total costs.
Table 3: Return on investment by World Bank income groups for the progress and ambitious scenarios
Total DALYs 
averted









Ambitious scenario 132 981 877 $238 759 $2 425 997 $1 347 913
Progress scenario 110 122 200 $194 942 $2 104 034 $1 152 233
Business-as-usual scenario 67 451 499 $120 058 $1 498 645 $810 395
Costs are given in 2018 US$. DALYs=disability-adjusted life-years. HEAR=hearing screening and intervention; ear 
disease prevention and management; access to technologies; and rehabilitation service provision.
Table 2: Total costs and benefits across scenarios
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In the sensitivity analysis, except for using a global value 
for monetising DALYs, none of the analyses resulted in a 
change in return on investment of more than 50%, except 
in low-income countries where all parameters except 
salary multiplier caused the return on investment to 
change by more than 50%. We note that the return on 
investment for low-income countries is numerically small 
(–0∙07; table 3), which causes even minor changes to 
appear relatively large. None of the parameter ranges 
explored caused the return on investment to become 
negative, except for the group of low-income countries; 
however, the lowest return on investment observed in this 
group was –0∙42, signifying that in the worst case, total 
benefits are 42% lower than total costs. Full details of the 
sensitivity analysis are provided in the appendix (p 58).
Discussion
In this study, we estimated the total resource requirements 
for implementing WHO’s recommended HEAR 
interventions across the life course,11 and we quantified 
the benefits in terms of DALYs averted and productivity 
gained from higher participation in the labour market. We 
estimated that scaling up the provision of HEAR requires 
a per capita total investment between years 2020 and 2030 
of less than US$20 in low-income countries and less than 
US$44 in high-income countries. This investment would 
achieve 90% coverage of hearing loss screening and 
interventions, and avoid almost 133 million DALYs at a 
global return on investment of 14∙81, or US$14∙81 of 
benefit for each US$1 invested. Our estimates for 
intervention costs in lower-middle-income countries—ie, 
less than US$20 over 10 years—are proportional to the 
US$58 per capita annual investment required to finance 
universal health coverage in this income group,16 
particularly as we do not take into account the integration 
of HEAR screening and service delivery with broader 
health system activities, which would yield cost-savings.
The investment case for hearing loss is favourable 
compared with other interventions. In the case of cancer, 
a recent economic analysis revealed that every US$1 
invested in cancer care in lower-middle-income countries 
is equivalent to a direct productivity return of US$2∙30 
and a social return based on both direct productivity and 
societal gains of US$9∙50.17 A much bigger investment 
case for prevention and control interventions for non-
communicable diseases, known as best buys, showed 
that for every US$1 invested in scaling up interventions 
in lower-middle-income countries, a return to society of 
at least US$7 is to be expected.18
Previous analysis has estimated the societal economic 
burden of unaddressed hearing loss as more than US$750 
billion annually. The analysis considered costs to the 
health-care and education systems resulting from 
unaddressed hearing loss, estimated globally by using 
data for the proportion of direct health-care costs 
attributable to hearing loss. The analysis also considered 
productivity costs, but only in countries with full 
employment, and conservatively valued each DALY gained 
at one-times GDP per capita net of productivity costs.10 
Our approach differs, in that we value productivity benefits 
in all countries regardless of full employment, and adhere 
to the most recent recommendations for the valuation of 
DALYs, which is 1∙5-times GDP per capita.19,20 To avoid 
double-counting productivity benefits, we subtracted the 
intrinsic value proportion, valuing each DALY at 0∙5-times 
GDP per capita. Results from our model suggest an even 
greater avoidable economic burden of hearing loss than 
previously estimated, with a 90% reduction of the burden 
of currently unmanaged hearing loss leading to 
productivity benefits of US$2∙4 trillion and monetised 
DALY benefits of US$1∙3 trillion.
Unaddressed hearing loss poses a substantial cost to 
countries because of its diverse effect on various sectors. 
The health-care sector bears the burden of high health-
care costs for children and adults because of failing to 
address hearing loss on time. Failing to diagnose and 
treat hearing loss from a very early age also poses a 
burden on the education sector due to costs of providing 
support to children with unaddressed hearing loss at 
school. Similarly, loss of productivity associated with 
unemployment and premature retirement among people 
with hearing loss substantially affects the labour sector. 
At a societal level, WHO estimates that the result of 
social isolation, communication difficulties, and stigma 
associated with unaddressed hearing loss costs societies 




















Low-income countries 6 235 396 $13 471 $6227 $6183 $2160 $1162 
Lower-middle-income countries 28 045 395 $50 628 $130 548 $109 733 $1805 –$2850*
Upper-middle-income countries 22 960 664 $37 519 $370 980 $216 490 $1634 –$14 523*
High-income countries 8 288 922 $17 047 $419 597 $205 112 $2057 –$48 565*
Total 65 530 378 $118 666 $927 352 $537 518 $1811 –$12 341*
Costs are given in 2018 US$. DALYs=disability-adjusted life-years. ICER=Incremental cost-effectiveness ratio. *Dominant.
Table 4: ICER of the ambitious scenario compared with the business-as-usual scenario
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When considered separately, the effectiveness and cost-
effectiveness of the different components of HEAR have 
been studied and reported in the literature. For instance, 
studies from different income settings have shown that 
implementing a newborn hearing screening followed by 
early intervention brings substantial advantages in terms 
of improved developmental outcomes in those receiving 
the required care.21–23,28,29 An analysis from China showed 
that newborn hearing screening and intervention 
resulted in a long-term cost-benefit ratio of 1 to 7∙52 in 
China,30 and a study from India estimated life-time 
savings of more than US$500 000 per child identified 
with hearing loss.31 Otitis media, which is a common 
childhood condition either acute or chronic in nature, as 
well as impacted wax, can be identified through ear and 
hearing screening undertaken at the school level so that 
children can be directed into the health system to receive 
the care they require.32 HEAR interventions also 
refer to risk-based screening for adults followed 
by diagnosis, provision of hearing technology where 
needed, and rehabilitation. Typically, this risk-based 
screening includes adults exposed to occupational noise 
and those older than 50 years. Identifying and addressing 
such hearing loss in a prompt manner can potentially 
reduce the productivity losses related to hearing loss and 
bring economic gains, as shown by our current analysis.
Screening for hearing loss, however, is most relevant 
for adults older than 50 years, as hearing loss increases 
exponentially with age, rising from 24% among those in 
their early 50s to more than 44% in those aged 70 years.1 
Active screening followed by interventions are relevant in 
this age group since people, even those living in well 
resourced settings, commonly wait for years before going 
for a hearing test or seeking care.33,34 The 2017 WHO 
guidelines for the integrated care of older people 
recommends that screening of hearing loss followed by 
provision of hearing aids should be offered to older 
people for timely identification and management.35 The 
financial implications and gains of such a service were 
studied in the UK through a modelling exercise, which 
showed that although this service increased the overall 
investment required, it had favourable incremental cost-
effectiveness ratio values of around £1000–2000 per 
quality-adjusted life-year. This UK study reached a 
conclusion that screening of people older than 55 years 
could result in a substantial public health gain and is a 
cost-effective means of improving participation and 
quality of life for older adults.36
An estimated US$239 billion would be needed to 
improve the coverage to 90% over the next 10 years. 
Although the numbers might seem staggering, the 
ambitious scenario requires less than US$45 per person 
over 10 years in high-income countries and less than 
US$20 per person in low-income countries. Given the 
potential health and societal gains, this investment is 
worth being considered by health policy makers. In 
addition to financial commitments, provision of the 
HEAR interventions can only be achieved when all pillars 
of the health system are strengthened. This goal includes 
establishing appropriate, evidence-based policies that 
address the priorities within each country in a manner 
most suitable for its health system; ensuring training, 
availability, and equitable distribution of the relevant 
health workforce; promoting access to hearing 
technologies through their inclusion in the country’s list 
of essential assistive products; and integrating appropriate 
indicators for ear and hearing care within health 
information systems.
Our study, however, has limitations. Firstly, we account 
only for staff and commodity costs, but not for 
programme costs associated with screening interventions 
(eg, training, logistics, monitoring, and evaluation). 
Secondly, we do not take into account any reduction in 
future resource use from intervening early in hearing 
loss. Thirdly, we assume a limited time horizon for 
benefits of hearing loss interventions, whereas in reality, 
several of the interventions modelled here would have 
lifetime benefits. Fourthly, we assume that individuals 
identified with hearing loss are treated according to that 
level of hearing loss only, and do not receive further 
interventions over the time horizon of the model. 
Individuals with moderate or higher levels of hearing 
loss would generally receive management and 
rehabilitation once, whereas individuals with mild 
hearing loss due to wax or otitis media could have 
recurring issues. Returning people with mild hearing 
loss to the population eligible for screening would 
marginally decrease the efficiency of screening. By 
contrast, continued management of individuals with 
identified hearing loss would lead to an improvement in 
the overall return on investment for HEAR, as the ratio 
of benefits to costs would be improved by a relative 
reduction in the cost of screening. Finally, although we 
explored the effect of central parameters in a one-way 
deterministic sensitivity analysis, our analysis does not 
incorporate the combined parameter uncertainty. 
Parameters specifically relating to the efficacy of hearing 
loss interventions in terms of disability level 
improvement, and the baseline service coverage levels 
for the 172 study countries, are based on expert opinion 
from within the WHO HEAR working group in lieu of 
granular evidence on all 172 countries individually.
In conclusion, investment over a 10-year period is 
expected to provide a return of nearly US$15 for every 
US$1 invested and result in health gains that translate to 
monetary values of more than US$1∙3 trillion and 
productivity gains of more than US$2 trillion. On the 
basis of health and societal gains, the HEAR package 
represents an attractive opportunity for policy makers to 
invest in ear and hearing care.
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